Skip to main content

Infection à Coxsackievirus

Maladie de la main, du pied et de la bouche

Professionnels de la santé

Les articles de référence professionnelle sont destinés aux professionnels de la santé. Ils sont rédigés par des médecins britanniques et s'appuient sur les résultats de la recherche et sur les lignes directrices britanniques et européennes. L'article sur la fièvre aphteuse vous sera peut-être plus utile, ou l'un de nos autres articles sur la santé.

Poursuivre la lecture ci-dessous

What is a Coxsackievirus?

The Coxsackieviruses are common pathogens causing a number of diseases, of which the most common is hand, foot and mouth disease (HFMD).

Virologie

The Coxsackieviruses are RNA viruses of the Picornaviridae family, Enterovirus genus which includes echoviruses and polioviruses. Infections are often asymptomatic. They are divided into groups A and B:

  • Coxsackievirus A:

    • Usually affects skin and mucous membranes.

    • Causes herpangina and HFMD.

    • There are a number of different viruses within the group. The most common causes of HFMD are Coxsackievirus A16 (CA16) along with the closely related enterovirus 71 (EV71).

  • Coxsackievirus B:

    • Usually affects the heart, lungs, pancreas and liver.

    • Causes Bornholm disease, hepatitis, myocarditis and pericarditis.

Coxsackieviruses of both types are a leading cause of aseptic meningitis. They may also cause nonspecific febrile and upper respiratory tract illnesses.

Spread is usually from the faeco-oral route or oral-oral route, with an incubation period of 2-6 days.

The virus is named after the town of Coxsackie in New York State.

Poursuivre la lecture ci-dessous

Épidémiologie1

Infection with this group of enteroviruses is very common. In temperate climates, it is most frequent in summer and autumn and, in the tropics, all year round.

Enterovirus disease, particularly HFMD tends to affect those aged under 10 but children of any age and adults can also be affected. It occurs worldwide, both on a sporadic basis and in epidemics. There have been a number of serious outbreaks of HFMD in the Western Pacific region. China has led the quest for vaccines, following a major outbreak with fatalities.

In the UK outbreaks occur regularly in nurseries, schools and childcare centres. Most adults have developed immunity.

Coxsackievirus symptoms

Hand, foot and mouth disease1

  • Most often caused by CA16 and the closely related EV71. Subtypes A 6 and 10 can also cause it but it can result from infection with other group A or B viruses.2 3

  • Usually a mild illness with a prodromal phase, followed by tender oral ulcerative lesions and then usually maculopapular lesions on the hands and feet; and sometimes the buttocks.

  • Rarely there are neurological or other complications which can be very severe.

  • See the separate article Hand foot and mouth disease for more information.

Herpangina4

  • Incubation period of about four days.

  • Affects mainly children up to the age of 10.

  • Mild pyrexia, headache, sore throat, dysphagia, loss of appetite and sometimes vomiting and abdominal pain.

  • Red spots appear on the uvula, soft palate and tonsils which develop into tiny grey-white papulovesicles, about 1 mm or 2 mm in diameter .

  • There is an erythematous halo, which progresses to a shallow ulcer.

  • It is caused mainly by CA16 but can involve other Coxsackievirus A serotypes and occasionally Coxsackievirus B (serotypes 1-5 ).

  • It resolves uneventfully in 5-10 days.

La maladie de Bornholm

  • Usually caused by Coxsackievirus B.

  • Pain on inspiration is similar to pleuritic pain and pulmonary embolism may be suspected. The muscles are locally tender.

  • Fever, headache or nonspecific abdominal pain - either as prodromal symptoms or with the onset of chest pain. May be myalgia elsewhere.

  • Duration is normally a few days, but may be ≤3 weeks; it can recur/relapse.

See the separate article Bornholm disease.

Myocardite

  • Coxsackievirus B is one of the more common causes of myocarditis, with potential to progress to dilated cardiomyopathy.5

  • Viral myocarditis may be asymptomatic, or may present with symptoms of heart failure and left ventricular dysfunction.

See the separate article Myocarditis for more information.

Péricardite

  • Coxsackievirus B is one of the more common causes of pericarditis.

  • The cardinal presenting symptom is chest pain. Typically, sharp, stabbing, central chest pain.

Aseptic meningitis6

  • Coxsackieviruses are one of the most common causes of aseptic (viral) meningitis.

  • In particular A and B viruses are involved.

  • There is a peak in summer months.

See the separate article Meningitis for more information.

Other clinical conditions

  • Coxsackie A viruses can cause a haemorrhagic conjunctivitis.

  • Coxsackievirus B5 causes pustular stomatitis with erythema multiforme.

  • Coxsackievirus A4 causes a widespread vesicular eruption.

  • There has been some investigation into Coxsackievirus B4 as a possible part of the aetiology of type 1 diabetes mellitus. There are also possible associations of Coxsackieviruses with postviral fatigue syndromes, Reye's syndrome and pancreatitis.

  • Coxsackievirus B1 has been reported as causing severe infection and death in neonates in America in 2007-2008.7

Poursuivre la lecture ci-dessous

Enquêtes1

Usually diagnosis is clinical but some laboratory tests are available.

  • Le virus peut être isolé à partir d'écouvillons de gorge, de vésicule ou de rectum (placés dans un milieu de transport viral) ou à partir d'une culture fécale. L'excrétion virale dans les selles peut être intermittente, de sorte que plusieurs échantillons peuvent être nécessaires.

  • IgM with enzyme-linked immunosorbent assay (ELISA) can aid diagnosis. Blood samples are required in the acute phase because IgM disappears rapidly.

  • La réaction en chaîne de la polymérase (PCR) a rendu possible le sous-typage des entérovirus et constitue de plus en plus le test de choix dans les centres spécialisés, bien qu'il soit rarement utilisé dans la pratique clinique de routine.

Coxsackievirus treatment1

  • There is no known treatment for Coxsackievirus infections, so management is supportive

  • For HFMD/herpangina:

    • Reassurance, and encourage adequate fluid intake.

    • Antipyretic analgesics such as paracetamol and ibuprofen are the main treatment.

    • Topical oral analgesic options are available although there is no evidence of efficacy and some cannot be used by children. Examples are lidocaine oral gel, benzydamine oral rinse or spray, choline salicylate oral gel, warm salty mouthwashes.

  • For other conditions:

    • Antiviral agents are not indicated. There is ongoing research into potential anti-viral agents and several show promise but are not yet at the clinical trial stage. 8

Advice for pregnant women1

  • There are no known adverse consequences for the fetus if a pregnant woman is in contact with HFMD.

  • Demandez l'avis d'un spécialiste si une femme développe une MFM dans les trois semaines précédant la date prévue de l'accouchement, car il existe un risque de transmission de l'infection au nouveau-né. Dans de rares cas, cela peut entraîner une infection grave chez le nouveau-né, bien que la maladie soit généralement bénigne.

  • Coxsackievirus B may cause an increase in early spontaneous abortions, stillbirths and (rarely) fetal myocarditis.9 10

Coxsackievirus prognosis1

These diseases tend to be self-limiting, although there are occasional case reports of adult fatalities.

The prognosis of HFMD is excellent, with the vast majority resolving spontaneously in 5-10 days. Those cases caused by Coxsackieviruses have less risk of developing neurological complications than those caused by EV17, although they can do very occasionally.

Aseptic meningitis usually resolves without sequelae but encephalitis is more likely to have adverse outcomes.

Although prognosis for those with Coxsackie B myocarditis or pericarditis is generally good, there are risks of complications such as dilated cardiomyopathy, dysrhythmias, cardiac failure and sudden cardiac death.

Coxsackievirus prevention

Good hygiene measures reduce spread of Coxsackieviruses within the family. Advise careful handwashing and drying after using the toilet. Advise against sharing cups, eating utensils, towels and clothing. Advise covering of the mouth and nose when coughing and sneezing, and hygienic disposal of tissues used.

Autres lectures et références

  • Zhang M, Wang H, Tang J, et al; Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatr. 2021 Mar 15;21(1):127. doi: 10.1186/s12887-021-02599-y.
  1. Maladie de la main, du pied et de la boucheNICE CKS, septembre 2024 (accès au Royaume-Uni uniquement)
  2. Downing C, Ramirez-Fort MK, Doan HQ, et al; Coxsackievirus A6 associated hand, foot and mouth disease in adults: clinical presentation and review of the literature. J Clin Virol. 2014 Aug;60(4):381-6. doi: 10.1016/j.jcv.2014.04.023. Epub 2014 May 9.
  3. Kimmis BD, Downing C, Tyring SLa fièvre aphteuse causée par le coxsackievirus A6 est en augmentation. Cutis. 2018 Nov;102(5):353-356.
  4. HerpanginaDermNet NZ
  5. Brunetti L, DeSantis ER; Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. 2008 Jan 15;65(2):132-7. doi: 10.2146/ajhp060586.
  6. Méningite - méningite bactérienne et maladie à méningocoquesNICE CKS, décembre 2024 (accès au Royaume-Uni uniquement)
  7. Wikswo ME, Khetsuriani N, Fowlkes AL, et al; Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007-2008. Clin Infect Dis. 2009 Sep 1;49(5):e44-51.
  8. Hand, Foot, and Mouth Disease Challenges and Its Antiviral Therapeutics; Vaccines, 2023
  9. Ornoy A, Tenenbaum ARésultats de la grossesse à la suite d'infections par les virus coxsackie, echo, rougeole, oreillons, hépatite, polio et encéphalite. Reprod Toxicol. 2006 mai;21(4):446-57. Epub 2006 Feb 9.
  10. Hwang JH, Kim JW, Hwang JY, et al; Coxsackievirus B infection is highly related with missed abortion in Korea. Yonsei Med J. 2014 Nov;55(6):1562-7. doi: 10.3349/ymj.2014.55.6.1562.
  11. Mao Q, Wang Y, Yao X, et al.Coxsackievirus A16 : épidémiologie, diagnostic et vaccin. Hum Vaccin Immunother. 2014;10(2):360-7. doi : 10.4161/hv.27087. Epub 2013 Nov 14.
  12. Li L, Yin H, An Z, et al; Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine. 2015 Feb 25;33(9):1107-12. doi: 10.1016/j.vaccine.2014.10.081. Epub 2014 Nov 8.
  13. Liang Z, Wang JLe vaccin EV71, un cadeau inestimable pour les enfants. Clin Transl Immunology. 2014 Oct 31;3(10):e28. doi : 10.1038/cti.2014.24. eCollection 2014 Oct.

Poursuivre la lecture ci-dessous

Historique de l'article

Les informations contenues dans cette page sont rédigées et évaluées par des cliniciens qualifiés.

Vérification de l'éligibilité à la grippe

Demandez, partagez, connectez-vous.

Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets liés à la santé.

vérificateur de symptômes

Vous ne vous sentez pas bien ?

Évaluez gratuitement vos symptômes en ligne